Piperidine → HCID 11454007, compound
Reaction equation
[NH:1]1[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1.CC(C)([O-])C.[K+].C([O:17][C:18](=[O:43])[CH2:19][CH2:20][NH:21][CH2:22][C:23]1[CH:42]=[CH:41][C:26]2[S:27][C:28]([C:30]3[CH:35]=[CH:34][C:33](Cl)=[C:32]([C:37]([F:40])([F:39])[F:38])[CH:31]=3)=[CH:29][C:25]=2[CH:24]=1)(C)(C)C>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[N:1]1([C:33]2[CH:34]=[CH:35][C:30]([C:28]3[S:27][C:26]4[CH:41]=[CH:42][C:23]([CH2:22][NH:21][CH2:20][CH2:19][C:18]([OH:43])=[O:17])=[CH:24][C:25]=4[CH:29]=3)=[CH:31][C:32]=2[C:37]([F:38])([F:40])[F:39])[CH2:6][CH2:5][CH2:4][CH2:3][CH2:2]1Participants
Conditions
- Temperature
- 60 °C
Procedure
Piperidine (30 μL, 2.0 mmol), Pd2 dba3 (2.7 mg, 0.003 mmol), potassium t-butoxide (59 mg, 0.53 mmol) and 1,3-bis-(2,6-diisopropylphenyl)-4,5-dihydroimidazol-2-ylidene HCl salt (2.6 mg, 0.006 mmol) are added sequentially to a solution of 3-{[2-(4-chloro-3-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]-amino}-propionic acid tert-butyl ester (72 mg, 0.15 mmol) in 1,4-dioxane (0.8 mL). The mixture is irradiated in a microwave at 100° C. for 1 hour. The reaction is quenched with water and the mixture is concentrated in vacuo. The residue is dissolved in THF and aqueous 2N NaOH (4 mL, 1:1 v/v), and stirred at 60° C. for 3 hours. It is concentrated and purified with preparative LCMS to afford 20 mg of 3-{[2-(4-piperidin-1-yl-3-trifluoromethyl-phenyl)-benzo[b]thiophen-5-ylmethyl]-amino}-propionic acid, which is converted to HCl salt: 1H NMR (400 MHz, CD3OD) δ 8.15-8.00 (m, 4H), 7.87 (s, 1H), 7.63 (d, 1H), 7.57 (d, 1H), 4.48 (s, 2H), 3.44 (t, 2H), 3.03 (t, 4H), 2.89 (t, 2H), 1.90-1.80 (m, 4H), 1.75-1.65 (m, 2H); MS (ES) 463.4 (M+H+).
Workup
- customThe mixture is irradiated in a microwave at 100° C. for 1 hour
- customThe reaction is quenched with water
- concentrationthe mixture is concentrated in vacuo
- dissolutionThe residue is dissolved in THF
- concentrationIt is concentrated
- custompurified with preparative LCMS
Sources & evidence
- ORD record
- ord-0bb9587da47c4820aa8131c5605964a5
- Source dataset
- uspto-grants-2010_07
- Patent number
- US07750021B2
Reaction notes
Loading…